Trend AnalysisOther Social Sciences
Political Economy of Global Vaccine Distribution: Equity Gaps and Market Mechanisms
COVID-19 exposed the brutal inequity of global vaccine distribution: wealthy nations hoarded doses while low-income countries waited. The political economy of vaccine access reveals how geopolitics, market structures, and institutional design determine who lives and who dies in pandemics.
By Sean K.S. Shin
This blog summarizes research trends based on published paper abstracts. Specific numbers or findings may contain inaccuracies. For scholarly rigor, always consult the original papers cited in each post.
During the COVID-19 pandemic, high-income countries secured enough vaccine doses to immunize their populations multiple times over while many low-income countries could not vaccinate even their healthcare workers. By mid-2021, over 75% of vaccine doses had been administered in high- and upper-middle-income countries. COVAX---the global initiative to ensure equitable distribution---delivered far below its targets, undermined by bilateral deals and export restrictions.
This was not a failure of science or manufacturing; it was a failure of political economy. The structures governing vaccine procurement, intellectual property, and international cooperation systematically favored wealthy nations.
Why It Matters
Infectious diseases do not respect borders. Unequal vaccine distribution prolongs pandemics globally, allows new variants to emerge in under-vaccinated populations, and creates both health crises and economic disruption. The lessons from COVID-19 must inform preparedness for future pandemics and ongoing challenges like HPV vaccination for cervical cancer prevention.
The Research Landscape
HPV Vaccination in LMICs
Ewongwo and Ngwa (2024), with 15 citations, guide global HPV vaccination access in low- and middle-income countries. Cervical cancer kills over 311,000 women annually, with 85% of deaths in LMICs---a preventable catastrophe given available vaccines. Their analysis identifies cost, cold-chain infrastructure, and cultural barriers as the primary obstacles to equitable HPV vaccine deployment.
Market Mechanism Design
Gui (2025) proposes a market-based mechanism for global vaccine procurement coalitions, analyzing the COVAX model and its limitations. The fundamental design problem: voluntary pooled procurement cannot compete with bilateral deals when supply is scarce. Their mechanism design approach creates incentive-compatible procurement structures that make joining coalitions rational for both wealthy and poor nations.
Vaccine Diplomacy
Ullah (2025) examines the intersection of vaccine diplomacy, migrant health equity, and COVID-19 responses. China and Russia used vaccine donations as geopolitical tools; wealthy nations used hoarding as bargaining leverage; and migrants---often ineligible for national vaccination programs---were systematically excluded. The analysis reveals how health equity is subordinated to geopolitical competition.
Middle Eastern Perspective
Al-Eitan, Almahdawi, and Abu Al-Eitan and Abu Khiarah (2025), with 4 citations, analyze vaccine access disparities in the Middle East, where conflict zones (Syria, Yemen), refugee populations, and political instability create unique distribution challenges absent from global models based on stable state infrastructure.
Vaccine Distribution Equity Mechanisms
<
| Mechanism | Goal | Effectiveness | Limitation |
|---|
| COVAX | Pooled procurement | Partial (fell short) | Voluntary, underfunded |
| Bilateral deals | National supply security | High (for rich nations) | Zero-sum, inequitable |
| Compulsory licensing | Local manufacturing | Moderate | IP opposition, quality |
| mRNA tech transfer | Capacity building | Promising | Infrastructure gaps |
| Vaccine diplomacy | Geopolitical influence | Variable | Strings attached |
What To Watch
The Pandemic Fund and new WHO Pandemic Treaty are attempting to codify equitable vaccine distribution for future pandemics. Whether these instruments will have enforcement mechanisms---or remain voluntary frameworks that collapse under the same pressures that undermined COVAX---will be tested when the next pandemic emerges.
During the COVID-19 pandemic, high-income countries secured enough vaccine doses to immunize their populations multiple times over while many low-income countries could not vaccinate even their healthcare workers. By mid-2021, over 75% of vaccine doses had been administered in high- and upper-middle-income countries. COVAX---the global initiative to ensure equitable distribution---delivered far below its targets, undermined by bilateral deals and export restrictions.
This was not a failure of science or manufacturing; it was a failure of political economy. The structures governing vaccine procurement, intellectual property, and international cooperation systematically favored wealthy nations.
Why It Matters
Infectious diseases do not respect borders. Unequal vaccine distribution prolongs pandemics globally, allows new variants to emerge in under-vaccinated populations, and creates both health crises and economic disruption. The lessons from COVID-19 must inform preparedness for future pandemics and ongoing challenges like HPV vaccination for cervical cancer prevention.
The Research Landscape
HPV Vaccination in LMICs
Ewongwo and Ngwa (2024), with 15 citations, guide global HPV vaccination access in low- and middle-income countries. Cervical cancer kills over 311,000 women annually, with 85% of deaths in LMICs---a preventable catastrophe given available vaccines. Their analysis identifies cost, cold-chain infrastructure, and cultural barriers as the primary obstacles to equitable HPV vaccine deployment.
Market Mechanism Design
Gui (2025) proposes a market-based mechanism for global vaccine procurement coalitions, analyzing the COVAX model and its limitations. The fundamental design problem: voluntary pooled procurement cannot compete with bilateral deals when supply is scarce. Their mechanism design approach creates incentive-compatible procurement structures that make joining coalitions rational for both wealthy and poor nations.
Vaccine Diplomacy
Ullah (2025) examines the intersection of vaccine diplomacy, migrant health equity, and COVID-19 responses. China and Russia used vaccine donations as geopolitical tools; wealthy nations used hoarding as bargaining leverage; and migrants---often ineligible for national vaccination programs---were systematically excluded. The analysis reveals how health equity is subordinated to geopolitical competition.
Middle Eastern Perspective
Al-Eitan, Almahdawi, and Abu Al-Eitan and Abu Khiarah (2025), with 4 citations, analyze vaccine access disparities in the Middle East, where conflict zones (Syria, Yemen), refugee populations, and political instability create unique distribution challenges absent from global models based on stable state infrastructure.
Vaccine Distribution Equity Mechanisms
<
| Mechanism | Goal | Effectiveness | Limitation |
|---|
| COVAX | Pooled procurement | Partial (fell short) | Voluntary, underfunded |
| Bilateral deals | National supply security | High (for rich nations) | Zero-sum, inequitable |
| Compulsory licensing | Local manufacturing | Moderate | IP opposition, quality |
| mRNA tech transfer | Capacity building | Promising | Infrastructure gaps |
| Vaccine diplomacy | Geopolitical influence | Variable | Strings attached |
What To Watch
The Pandemic Fund and new WHO Pandemic Treaty are attempting to codify equitable vaccine distribution for future pandemics. Whether these instruments will have enforcement mechanisms---or remain voluntary frameworks that collapse under the same pressures that undermined COVAX---will be tested when the next pandemic emerges.
References (8)
[1] Ewongwo, A., Sahor, A. F., & Ngwa, W. (2024). HPV vaccination access in LMICs. Frontiers in Oncology.
[2] Gui, L. (2025). Market-Based Mechanism for Vaccine Procurement Coalitions. MSOM.
[3] Ullah, A. (2025). Vaccine diplomacy and migrant health equity. Third World Quarterly.
[4] Al-Eitan, L., Almahdawi, D. L., & Abu Khiarah, R. A. (2025). Vaccine Access in the Middle East. Vaccines.
Ewongwo, A., Sahor, A. F., Ngwa, W., & Nwachukwu, C. (2024). A guide to global access to HPV vaccination to all women in low- and middle-income countries; a minireview of innovation and equity. Frontiers in Oncology, 14.
Gui, L. (2026). A Market-Based Mechanism for Global Vaccine Procurement Coalitions. Manufacturing & Service Operations Management, 28(1), 100-116.
Ullah, A. A. (2025). The politics of access: vaccine diplomacy, migrant health equity and the COVID-19 response. Third World Quarterly, 46(12), 1439-1460.
AL-Eitan, L. N., Almahdawi, D. L., Abu Khiarah, R. A., & Alghamdi, M. A. (2025). Bridging Gaps in Vaccine Access and Equity: A Middle Eastern Perspective. Vaccines, 13(8), 806.